CN114470149A - Antibacterial solution with size-controllable protein-based nanoparticles - Google Patents
Antibacterial solution with size-controllable protein-based nanoparticles Download PDFInfo
- Publication number
- CN114470149A CN114470149A CN202210095697.XA CN202210095697A CN114470149A CN 114470149 A CN114470149 A CN 114470149A CN 202210095697 A CN202210095697 A CN 202210095697A CN 114470149 A CN114470149 A CN 114470149A
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- protein
- acid
- based nanoparticles
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 102
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 33
- 239000003607 modifier Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 108010014251 Muramidase Proteins 0.000 claims abstract description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 10
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 10
- 229960000274 lysozyme Drugs 0.000 claims abstract description 10
- 239000004325 lysozyme Substances 0.000 claims abstract description 10
- 239000000499 gel Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000006185 dispersion Substances 0.000 claims abstract description 6
- 238000005507 spraying Methods 0.000 claims abstract description 5
- 235000018102 proteins Nutrition 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 20
- 229910045601 alloy Inorganic materials 0.000 claims description 15
- 239000000956 alloy Substances 0.000 claims description 15
- -1 thyrolactoglobulin Proteins 0.000 claims description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102100033468 Lysozyme C Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 102000004407 Lactalbumin Human genes 0.000 claims description 6
- 108090000942 Lactalbumin Proteins 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 6
- 108090000284 Pepsin A Proteins 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 229940014259 gelatin Drugs 0.000 claims description 6
- 229910010272 inorganic material Inorganic materials 0.000 claims description 6
- 239000011147 inorganic material Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 229940111202 pepsin Drugs 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920002643 polyglutamic acid Polymers 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 6
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229960005188 collagen Drugs 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 4
- 108010076119 Caseins Proteins 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 4
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 229940083542 sodium Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- 229910000531 Co alloy Inorganic materials 0.000 claims description 3
- 108010061642 Cystatin C Proteins 0.000 claims description 3
- 102000012192 Cystatin C Human genes 0.000 claims description 3
- 102100030497 Cytochrome c Human genes 0.000 claims description 3
- 108010075031 Cytochromes c Proteins 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 229920002752 Konjac Polymers 0.000 claims description 3
- 108010063045 Lactoferrin Proteins 0.000 claims description 3
- 102000010445 Lactoferrin Human genes 0.000 claims description 3
- 108010060630 Lactoglobulins Proteins 0.000 claims description 3
- 102000008192 Lactoglobulins Human genes 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 108010062374 Myoglobin Proteins 0.000 claims description 3
- 102100030856 Myoglobin Human genes 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 3
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 108090000637 alpha-Amylases Proteins 0.000 claims description 3
- 102000004139 alpha-Amylases Human genes 0.000 claims description 3
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 3
- 229940024171 alpha-amylase Drugs 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000003575 carbonaceous material Substances 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229940071870 hydroiodic acid Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 239000007769 metal material Substances 0.000 claims description 3
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 3
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920002530 polyetherether ketone Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 239000002861 polymer material Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004804 polysaccharides Chemical class 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 239000012286 potassium permanganate Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 239000004945 silicone rubber Substances 0.000 claims description 3
- PNYYBUOBTVHFDN-UHFFFAOYSA-N sodium bismuthate Chemical compound [Na+].[O-][Bi](=O)=O PNYYBUOBTVHFDN-UHFFFAOYSA-N 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 3
- 150000001868 cobalt Chemical class 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 238000004528 spin coating Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 229920004933 Terylene® Polymers 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 235000019823 konjac gum Nutrition 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 10
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 235000013373 food additive Nutrition 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 239000000606 toothpaste Substances 0.000 abstract description 2
- 229940034610 toothpaste Drugs 0.000 abstract description 2
- 102000016943 Muramidase Human genes 0.000 abstract 1
- 238000000889 atomisation Methods 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 12
- 241000209094 Oryza Species 0.000 description 10
- 235000007164 Oryza sativa Nutrition 0.000 description 10
- 235000009566 rice Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- MPMSMUBQXQALQI-UHFFFAOYSA-N cobalt phthalocyanine Chemical class [Co+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 MPMSMUBQXQALQI-UHFFFAOYSA-N 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 229940069002 potassium dichromate Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B9/00—Preservation of edible seeds, e.g. cereals
- A23B9/16—Preserving with chemicals
- A23B9/24—Preserving with chemicals in the form of liquids or solids
- A23B9/26—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B9/00—Preservation of edible seeds, e.g. cereals
- A23B9/16—Preserving with chemicals
- A23B9/24—Preserving with chemicals in the form of liquids or solids
- A23B9/26—Organic compounds; Microorganisms; Enzymes
- A23B9/28—Microorganisms; Enzymes; Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Dentistry (AREA)
- Polymers & Plastics (AREA)
- Agronomy & Crop Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses an antibacterial solution with size-controllable protein-based nanoparticles, which is prepared by dissolving protein and a modifier in water, adjusting the pH value to 3-8 with NaOH, and reacting at room temperature for 5-10 hours to obtain a dispersion solution with size-controllable protein-based nanoparticles. The invention utilizes the antibacterial property of natural proteins such as lysozyme and the like, and modifies the natural proteins by a modifier, so that the antibacterial property of the natural proteins is improved. The antibacterial liquid can also inhibit the formation of bacterial biofilm and remove the formed biofilm. The antibacterial liquid can be prepared in large volume, has high biocompatibility and simple preparation method, and cannot generate drug resistance. The antibacterial agent can also be made into antibacterial coatings, gels, powder, tablets and other antibacterial agents in various forms, the use modes of the antibacterial agent are diversified, the antibacterial agent comprises oral administration, intramuscular injection, intravenous injection, patches, microneedles, atomization inhalation, spraying, gargle, toothpaste, food additives and the like, and bacterial drug resistance caused by improper use of antibiotics can be effectively avoided.
Description
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to an antibacterial liquid with size-controllable protein-based nanoparticles, which has strong bactericidal capacity on bacteria and fungi and also has strong antiviral capacity.
Background
Bacterial infections, one of the ten leading causes of death worldwide, threaten the lives of countless people. The discovery of penicillin in the last 20 th century has created a new antibiotic antibacterial chapter, and is the most great invention in the 20 th century. Subsequent abuse of antibiotics also greatly contributed to the development of bacterial resistance. Each new antibiotic can bring new drug-resistant strains in clinical use, and even generate multi-drug-resistant 'super drug-resistant bacteria'. Antibiotic resistance is an increasing problem worldwide. According to the statistics of the world health organization, the death caused by infection in patients in the world is more than 85 percent of the death caused by the infection of drug-resistant bacteria, and the malignant result brings great burden to the life health and the economy of human beings. More than 70 million people die from drug resistant diseases each year. The threat of the "post-antibiotic age" urgently requires new antibacterial materials and methods to replace antibiotics, coping with this crisis.
Antibacterial enzymes such as lysozyme, lysostaphin and the like have gained increasing attention in recent years due to their high biocompatibility. But its development is limited by its limitations in its antimicrobial capacity. Therefore, it is a great challenge to modify it, maintain its biocompatibility, and further improve its antibacterial performance.
Disclosure of Invention
The invention aims to overcome the defect of antibiotic resistance and provide the multifunctional antibacterial liquid which is simple to prepare, is biologically safe, does not cause bacterial resistance and can effectively remove bacterial biofilms.
Aiming at the purposes, the antibacterial liquid adopted by the invention is a dispersion liquid of protein-based nanoparticles with controllable sizes, which is obtained by dissolving a modifier and proteins in water, adjusting the pH to 3-8 by NaOH, and reacting for 5-10 hours at room temperature.
The protein is one or more of lysozyme, lactalbumin, insulin, beta-lactoglobulin, bovine serum albumin, human serum albumin, alpha-lactalbumin, fibrinogen, beta-amyloid, transferrin, collagen, pepsin, keratin, myoglobin, hemoglobin, soybean protein, lactoferrin, albumin, thyrolactoglobulin, prion protein, Abeta peptide, alpha-synuclein, alpha-amylase, pepsin, horseradish peroxidase, ribonuclease A, cytochrome c, cystatin C, DNA polymerase, casein, Huntington protein and immunoglobulin light chain.
The modifier is one or more of cysteine, tris (2-carboxyethyl) phosphine hydrochloride, glutathione, mercaptoethanol, dithiothreitol, dimercaptosuccinic acid, sodium sulfite, beta-mercaptoethanol, hydrogen peroxide, ozone, sodium ferrate, trivalent cobalt salt, chlorate, potassium permanganate, persulfate, potassium dichromate, concentrated sulfuric acid, hydrochloric acid, nitric acid, hydrobromic acid, hydroiodic acid, perchloric acid, fluorine gas, chlorine gas, sodium bismuthate, periodic acid, lead dichloride, guanidine hydrochloride, urea, trifluoroethanol, hexafluoroisopropanol and trifluoroacetic acid.
The antibacterial liquid preferably has a mass ratio of protein to modifier of 1: 0.5 to 2.
The concentration of the protein dissolved in water is preferably 1 to 50mg/mL and the concentration of the modifier is preferably 1 to 50 mg/mL.
In the antibacterial liquid, the size of the protein-based nanoparticles is 10-200 nm.
And spin-coating or spray-coating the antibacterial liquid on the surfaces of different base materials to be modified to obtain the antibacterial coating. The substrate to be modified may be any material for film formation, and is not limited to any shape or material. The method specifically comprises the following steps: (1) metal material: stainless steel, titanium and its alloys, cobalt-based alloys, nickel-titanium alloys, magnesium and its alloys, zinc and its alloys, iron and its alloys, and the like; (2) inorganic materials: inorganic materials such as silicon dioxide, titanium dioxide, carbon materials, silicon, and titanium nitride; (3) high polymer material: dacron (PET), polyvinyl alcohol (PVALC), Polyethylene (PE), Polytetrafluoroethylene (PTFE), polyvinyl chloride (PVC), Polystyrene (PS), Polyurethane (PU), polypropylene (PP), polyamide, Polycarbonate (PC), polyacrylonitrile, polyacrylic acid (PAA) and its derivatives, polyetheretherketone, silicone rubber, polylactic acid, polyglycolide, polylactide, polycaprolactone, and the like; (4) natural biological material: plastic starch-based materials (PSM), sodium alginate, collagen, fibrin, sodium hyaluronate, gelatin and the like; (5) artificially synthesizing a polypeptide hydrogel material: poly-L-glutamic acid, poly-L-lysine, and the like. The type of the base material is not limited to the above materials, and may be a mixture of the above materials.
And (3) dissolving the macromolecular compound with the mass fraction of 5-30% in the antibacterial liquid to obtain the antibacterial gel. Wherein the macromolecular compound comprises one or more of starch, cellulose, gelatin, pectin, konjac glucomannan, carrageenan, Arabic gum, agar, seaweed gel, alginic acid, hyaluronic acid, chitosan, carrageenan, polysaccharide derivatives, collagen, poly-L-lysine and poly-L-glutamic acid.
Dialyzing the antibacterial liquid for 1 day, and freeze-drying to obtain an antibacterial powder preparation; and tabletting the powder preparation in a tabletting machine to obtain the antibacterial tablet preparation.
The invention has the following beneficial effects:
1. the antibacterial liquid disclosed by the invention can play an antibacterial role without adding antibiotics, can effectively avoid bacterial drug resistance caused by improper use of antibiotics, and can not cause bacteria to generate drug resistance.
2. The antibacterial liquid of the invention has net positive charge, good biocompatibility and high bactericidal performance of nano materials, and has very high antiviral performance besides good antibacterial effect on bacteria and fungi.
3. The antibacterial liquid can effectively inhibit the formation of a biological membrane, and has a good removing effect on the formed biological membrane.
4. The antibacterial liquid can inhibit the mildew of rice, traditional Chinese medicines and the like in a humid environment.
5. The antibacterial liquid has the advantages of simple preparation method, biological safety and controllable nano-particle size, can be prepared into antibacterial agents in various forms such as antibacterial coatings, gels, powder, tablets and the like, and has more diversified use modes including oral administration, intramuscular injection, intravenous injection, patches, micro-needles, atomized inhalation, spraying, gargle, toothpaste, food additives and the like.
Drawings
FIG. 1 is a size distribution diagram of nanoparticles in the antibacterial solution of example 1.
FIG. 2 is a size distribution diagram of nanoparticles in the antibacterial solution of example 2.
FIG. 3 is a graph showing the bactericidal activity against Staphylococcus aureus, Escherichia coli, and Candida tropicalis in the antibacterial liquid of example 1.
FIG. 4 is a graph showing the antiviral effect of the antibacterial solution of example 1 on adenovirus.
FIG. 5 shows the results of the hemolysis test of the antibacterial solution of example 1.
FIG. 6 shows the results of the test for the resistance of Staphylococcus aureus to the antibacterial solution of example 1.
FIG. 7 shows the results of the rice mold-proofing test using the antibacterial solution of example 1.
Detailed Description
The invention will be further described in detail with reference to the following figures and examples, but the scope of the invention is not limited to these examples.
Example 1
5mg/mL L-cysteine aqueous solution and 5mg/mL lysozyme aqueous solution were mixed in equal volume at room temperature, and then the pH was adjusted to 6.5, 7.0, and 7.5 with 1mol/L sodium hydroxide aqueous solution, respectively, and reacted at room temperature for 8 hours to obtain an antibacterial solution. As can be seen from FIG. 1, the nanoparticles of the obtained antibacterial liquid are controllable from 10nm to 100 nm.
Example 2
After mixing a 10mg/mL glutathione aqueous solution and a 10mg/mL lysozyme aqueous solution in equal volume at room temperature, adjusting the pH to 6.5, 7.0 and 7.5 respectively by using a 1mol/L sodium hydroxide aqueous solution, and reacting for 8 hours at room temperature to obtain an antibacterial solution. As can be seen from FIG. 2, the nanoparticles in the obtained antibacterial liquid can be controlled from 10nm to 200 nm.
Example 3
At room temperature, 5mg/mL bovine serum albumin aqueous solution and 5mg/mL tris (2-carboxyethyl) phosphine hydrochloride aqueous solution were mixed at a volume ratio of 2: 1, adjusting the pH to 7.0, 7.5 and 8.0 respectively by using 1mol/L sodium hydroxide aqueous solution, and reacting for 5 hours at room temperature to obtain the antibacterial solution.
Example 4
At room temperature, mixing a 5mg/mL glutathione aqueous solution and a 5mg/mL lysozyme aqueous solution according to a volume ratio of 1: 2, adjusting the pH to 7.0 by using a 1mol/L sodium hydroxide aqueous solution, and reacting at room temperature for 8 hours to obtain an antibacterial solution.
Example 5
At room temperature, mixing a 15mg/mL aqueous solution of tris (2-carboxyethyl) phosphine hydrochloride and a 15mg/mL aqueous solution of lactalbumin according to a volume ratio of 1: 2, adjusting the pH to 8.0 by using a 1mol/L sodium hydroxide aqueous solution, and reacting at room temperature for 8 hours to obtain an antibacterial solution.
Example 6
Mixing 10mg/mL L-cysteine aqueous solution and 10mg/mL lysozyme aqueous solution in equal volume at room temperature, adjusting the pH to 6.5 with 1mol/L sodium hydroxide aqueous solution, and reacting at room temperature for 8 hours to obtain the antibacterial solution. The antibacterial liquid is coated on a quartz plate in a spinning mode, and the antibacterial coating can be obtained.
Example 7
After mixing a 10mg/mL glutathione aqueous solution and a 10mg/mL lysozyme aqueous solution in equal volume at room temperature, adjusting the pH to 7.0 by using a 1mol/L sodium hydroxide aqueous solution, and reacting for 8 hours at room temperature to obtain an antibacterial solution. And spraying the antibacterial liquid on the surface of PP to obtain the antibacterial coating.
Example 8
After 5mg/mL tris (2-carboxyethyl) phosphine hydrochloride aqueous solution and 5mg/mL insulin aqueous solution were mixed in equal volumes at room temperature, the pH was adjusted to 8.0 with 1mol/L sodium hydroxide aqueous solution, and the reaction was carried out at room temperature for 8 hours to obtain an antibacterial solution. The antibacterial liquid is sprayed on the surface of the stainless steel to obtain the antibacterial coating.
Example 9
At room temperature, 5mg/mL dithiothreitol aqueous solution and 5mg/mL human serum albumin aqueous solution were mixed in a volume ratio of 2: 1, adjusting the pH to 8.0 by using a 1mol/L sodium hydroxide aqueous solution, and reacting at room temperature for 8 hours to obtain an antibacterial solution. 0.15g of gelatin is dissolved in 1mL of antibacterial solution to obtain the antibacterial gel.
Example 10
Mixing a 10mg/mL mercaptoethanol aqueous solution and a 10mg/mL lysozyme aqueous solution in equal volume at room temperature, adjusting the pH to 7.0 by using a 1mol/L sodium hydroxide aqueous solution, and reacting at room temperature for 8 hours to obtain the antibacterial liquid. 0.2g of chitosan is dissolved in 1mL of antibacterial solution to obtain the antibacterial gel.
In order to prove the beneficial effects of the invention, the inventor carries out various performance tests on the antibacterial liquid of the example 1, and the specific experiments are as follows:
1. antimicrobial Activity test
The antibacterial activity of the above antibacterial liquid was evaluated based on a colony counting method using two kinds of bacteria (staphylococcus adamantine ATCC6538 and escherichia coli ATCC25922) and one kind of fungus (candida tropicalis ATCC 1369). Before conducting the in vitro antibacterial test, the bacterial suspension was incubated overnight at 37 ℃ in a centrifuge tube of 50mL MHB medium with shaking at 70 rpm. The bacteria or fungi are allowed to grow in logarithmic phase. The cells were collected by centrifugation and washed three times with PBS buffer to remove residual medium, followed by 108The concentration of CFU/mL was resuspended in PBS buffer. 100. mu.L of the resuspended suspension was added to 900. mu.L of the antibacterial solution, incubated at 37 ℃ for 8 hours, and the bacterial or fungal suspension was serially diluted and plated on MHA plates. After incubation of these MHA plates at 37 ℃ for 24 hours, the number of colonies was recorded. The antibacterial activity is represented by a bactericidal rate, which is calculated according to the following formula:
wherein C0 represents the number of colonies in blank PBS and C is the number of colonies in the antibacterial solution. The results of the experiment are shown in FIG. 3. The result shows that the antibacterial liquid has high bactericidal rate on gram-positive bacteria, gram-negative bacteria and candida tropicalis.
2. Antiviral Properties
2mL of the complete medium is used for preparing the culture medium with the density of 3-5 multiplied by 104Inoculating 293T cell suspension per mL into a 6-well plate, culturing at 37 ℃ for 16-24 hours until the cell confluency reaches 30%, discarding supernatant in the well plate, adding 1mL of complete culture medium, and adding adenovirus solution (diluting adenovirus to uniform titer of 1 × 10 by using basal medium)8TU/mL), 10. mu.L of PBS buffer was added to three wells, and 10. mu.L of the antibacterial solution was added to the other three wells. Mixing and culturing. After 48 hours, the cells were photographed under a fluorescence microscope and the number of GFP-positive cells was counted to calculate the infection rate. The results in FIG. 4 show that the cells to which 10. mu.L of the antibacterial solution was added were not infected with viruses, indicating that the antibacterial solution had a good antiviral ability.
3. Hemolysis test
Fresh blood was centrifuged and red blood cells were collected and washed three times with PBS buffer. Red blood cells were dispersed in PBS buffer at 5% (v/v). After diluting the antibacterial solution to different concentrations, 100. mu.L of the red blood cell dispersion was added to 900. mu.L of the antibacterial solution of different concentrations, and incubated at 37 ℃ for 1 hour. A blank group was prepared by adding 100. mu.L of the red blood cell dispersion to 900. mu.L of PBS buffer, and a positive control group was prepared by adding 100. mu.L of the red blood cell dispersion to 900. mu.L of secondary water. After centrifugation, the supernatant was collected for OD measurement540. The hemolysis rate is calculated as follows:
the results in FIG. 5 show that the hemolysis rate of the antibacterial solution is still low when the antibacterial solution reaches 10mg/mL, and thus the blood compatibility of the antibacterial solution is good.
4. Drug resistance testing
10mL of Staphylococcus aureus in logarithmic growth phase in MHB was taken and diluted to 10% with MHB5CFU/mL was used as the working solution. The antibacterial solution was dispersed in MHB at different concentrations, and then 100. mu.L of the mixture was mixed with 100. mu.L of the working solution and added to a 96-well plate. Placing the well plate in a microplate reader, measuring OD590 at 37 ℃, and observing bacterial growthThe situation is. Wherein the minimum concentration capable of inhibiting the growth of bacteria is the Minimum Inhibitory Concentration (MIC) of the antibacterial liquid. The bacteria were then cultured at 0.125 × MIC. The above process was repeated again with the bacteria in log phase. Fig. 6 can be obtained. The results show that the obtained antibacterial solution does not induce the bacteria to generate drug resistance.
5. Anti-mildew experiment of rice
Dividing 10g of rice into two groups on average, and soaking one group in deionized water for 0.5h to obtain a blank group; the other group was immersed in the antimicrobial solution of example 1 at pH 7.0 for 0.5h, and the test group was obtained. After being dried, the two groups of rice are placed in a constant temperature and humidity box (25 ℃, 99% RH), and the mildew condition of the two groups of rice is observed every day. As shown in FIG. 7, the rice in the blank group had significantly mildewed on day 10, with large mildew stains on day 34, and was completely covered with the mold by day 62, while the rice in the experimental group remained identical to the rice in the first day at day 62. Therefore, the antibacterial liquid can effectively inhibit the mildew of rice.
The protein in the above embodiments may be beta-lactoglobulin, alpha-lactalbumin, fibrinogen, beta-amyloid protein, transferrin, collagen, pepsin, keratin, myoglobin, hemoglobin, soy protein, lactoferrin, albumin, thyroglobulin, prion protein, Abeta peptide, alpha-synuclein, alpha-amylase, pepsin, horseradish peroxidase, ribonuclease A, cytochrome c, cystatin C, DNA polymerase, casein, Huntington protein, immunoglobulin light chain, and the modifier may be dimercaptosuccinic acid, sodium sulfite, beta-mercaptoethanol, hydrogen peroxide, ozone, sodium ferrate, cobaltous salt, chlorate, potassium permanganate, persulfate, potassium dichromate, concentrated sulfuric acid, ozone, sodium ferrate, sodium ascorbate, sodium caseinate, sodium sulfate, potassium dichromate, concentrated sulfuric acid, sodium sulfate, sodium alginate, etc., and the like, Any one or more of hydrochloric acid, nitric acid, hydrobromic acid, hydroiodic acid, perchloric acid, fluorine gas, chlorine gas, sodium bismuthate, periodic acid, lead dichloride, guanidine hydrochloride, urea, trifluoroethanol, hexafluoroisopropanol and trifluoroacetic acid.
The antibacterial liquid can be spin-coated or spray-coated on the surfaces of different base materials to obtain the antibacterial coating. The substrate may be any material for film formation that is available, and is hardly limited to shape and material. The method specifically comprises the following steps: (1) metal material: stainless steel, titanium and its alloys, cobalt-based alloys, nickel-titanium alloys, magnesium and its alloys, zinc and its alloys, iron and its alloys, and the like; (2) inorganic materials: inorganic materials such as silicon dioxide, titanium dioxide, carbon materials, silicon, and titanium nitride; (3) high polymer material: dacron (PET), polyvinyl alcohol (PVALC), Polyethylene (PE), Polytetrafluoroethylene (PTFE), polyvinyl chloride (PVC), Polystyrene (PS), Polyurethane (PU), polypropylene (PP), polyamide, Polycarbonate (PC), polyacrylonitrile, polyacrylic acid (PAA) and its derivatives, polyetheretherketone, silicone rubber, polylactic acid, polyglycolide, polylactide, polycaprolactone, and the like; (4) natural biological material: plastic starch-based materials (PSM), sodium alginate, collagen, fibrin, sodium hyaluronate, gelatin and the like; (5) artificially synthesizing a polypeptide hydrogel material: poly-L-glutamic acid, poly-L-lysine, and the like. The type of the base material is not limited to the above materials, and may be a mixture of the above materials.
The macromolecular compound with the mass fraction of 5-30% is dissolved in the antibacterial liquid to obtain the antibacterial gel. Wherein the macromolecular compound comprises one or more of starch, cellulose, gelatin, pectin, konjac glucomannan, carrageenan, Arabic gum, agar, seaweed gel, alginic acid, hyaluronic acid, chitosan, carrageenan, polysaccharide derivatives, collagen, poly-L-lysine and poly-L-glutamic acid.
Dialyzing the antibacterial solution for 1 day, and freeze-drying to obtain an antibacterial powder preparation; and tabletting the powder preparation in a tabletting machine to obtain the antibacterial tablet preparation.
Claims (10)
1. An antiseptic solution having protein-based nanoparticles of controlled size, characterized by: the antibacterial solution is a dispersion solution of protein-based nanoparticles with controllable sizes, which is obtained by dissolving protein and a modifier in water, adjusting the pH value to 3-8 with NaOH, and reacting at room temperature for 5-10 hours.
2. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized by: the protein is any one or more of lysozyme, lactalbumin, insulin, beta-lactoglobulin, bovine serum albumin, human serum albumin, alpha-lactalbumin, fibrinogen, beta-amyloid, transferrin, collagen, pepsin, keratin, myoglobin, hemoglobin, soybean protein, lactoferrin, albumin, thyrolactoglobulin, prion protein, Abeta peptide, alpha-synuclein, alpha-amylase, pepsin, horseradish peroxidase, ribonuclease A, cytochrome c, cystatin C, DNA polymerase, casein, Huntington protein and immunoglobulin light chain.
3. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized in that: the modifier is one or more of cysteine, tris (2-carboxyethyl) phosphine hydrochloride, glutathione, mercaptoethanol, dithiothreitol, dimercaptosuccinic acid, sodium sulfite, beta-mercaptoethanol, hydrogen peroxide, ozone, sodium ferrate, trivalent cobalt salt, chlorate, potassium permanganate, persulfate, potassium dichromate, concentrated sulfuric acid, hydrochloric acid, nitric acid, hydrobromic acid, hydroiodic acid, perchloric acid, fluorine gas, chlorine gas, sodium bismuthate, periodic acid, lead dichloride, guanidine hydrochloride, urea, trifluoroethanol, hexafluoroisopropanol and trifluoroacetic acid.
4. The antiseptic solution with controllable size protein-based nanoparticles according to any one of claims 1 to 3, characterized in that: the mass ratio of the protein to the modifier is 1: 0.5 to 2.
5. The antiseptic solution with controlled size protein-based nanoparticles of claim 4, characterized by: dissolving the modifier and the protein in water to ensure that the concentration of the protein in the water is 1-50 mg/mL and the concentration of the modifier in the water is 1-50 mg/mL.
6. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized in that: in the antibacterial liquid, the size of the protein-based nanoparticles is 10-200 nm.
7. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized by: and spin-coating or spray-coating the antibacterial liquid on the surface of the substrate to be modified to obtain the antibacterial coating.
8. The antiseptic solution with controlled size protein-based nanoparticles of claim 7, characterized in that the substrate to be modified comprises any one of the following materials:
(1) metal material: stainless steel, titanium and its alloys, cobalt-based alloys, nickel-titanium alloys, magnesium and its alloys, zinc and its alloys, iron and its alloys;
(2) inorganic materials: inorganic materials such as silicon dioxide, titanium dioxide, carbon materials, silicon, and titanium nitride;
(3) high polymer material: terylene, polyvinyl alcohol, polyethylene, polytetrafluoroethylene, polyvinyl chloride, polystyrene, polyurethane, polypropylene, polyamide, polycarbonate, polyacrylonitrile, polyacrylic acid and derivatives thereof, polyether ether ketone, silicone rubber, polylactic acid, polyglycolide, polylactide and polycaprolactone;
(4) natural biological material: plastic starch-based materials, sodium alginate, collagen, fibrin, sodium hyaluronate and gelatin;
(5) artificially synthesizing a polypeptide hydrogel material: poly-L-glutamic acid, poly-L-lysine.
9. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized by: dissolving a macromolecular compound with the mass fraction of 5-30% in the antibacterial liquid to obtain antibacterial gel; the polymer compound comprises one or more of starch, cellulose, gelatin, pectin, konjac gum, carrageenan, arabic gum, agar, alginate jelly, alginic acid, hyaluronic acid, chitosan, carrageenan, polysaccharide derivatives, collagen, poly-L-lysine and poly-L-glutamic acid.
10. The antiseptic solution with controlled size protein-based nanoparticles of claim 1, characterized by: dialyzing the antibacterial solution and freeze-drying to obtain an antibacterial powder preparation; and tabletting the powder preparation in a tabletting machine to obtain the antibacterial tablet preparation.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311404388.7A CN117442702A (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
CN202210095697.XA CN114470149B (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210095697.XA CN114470149B (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311404388.7A Division CN117442702A (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114470149A true CN114470149A (en) | 2022-05-13 |
CN114470149B CN114470149B (en) | 2024-01-23 |
Family
ID=81475808
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210095697.XA Active CN114470149B (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
CN202311404388.7A Pending CN117442702A (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311404388.7A Pending CN117442702A (en) | 2022-01-26 | 2022-01-26 | Antibacterial liquid with controllable-size protein-based nanoparticles |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN114470149B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115444031A (en) * | 2022-09-01 | 2022-12-09 | 陕西师范大学 | Protein-based fruit antibacterial fresh-keeping edible coating and preparation method and application thereof |
CN115531239A (en) * | 2022-05-19 | 2022-12-30 | 海默斯(重庆)医学生物技术有限公司 | Nano-particles, toothpaste and preparation method thereof |
CN115843794A (en) * | 2022-12-13 | 2023-03-28 | 贵州大学 | Nano system of plant protein-based drug-encapsulated molecules, preparation method and application |
CN117777492A (en) * | 2023-11-14 | 2024-03-29 | 宁波大学 | Preparation method and application of normal-temperature antibacterial hydrogel based on fibrinogen and carrageenan |
WO2024179225A1 (en) * | 2023-02-28 | 2024-09-06 | 陕西师范大学 | Cleaning agent for material surface |
CN117777492B (en) * | 2023-11-14 | 2024-09-27 | 宁波大学 | Preparation method and application of normal-temperature antibacterial hydrogel based on fibrinogen and carrageenan |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1616092A (en) * | 2004-10-19 | 2005-05-18 | 上海新药研究开发中心 | Compound lysoamidase spray agent and preparing method |
CN103520734A (en) * | 2013-09-29 | 2014-01-22 | 中国科学院过程工程研究所 | Albumin-based nano particle and preparation method and application thereof |
CN105475359A (en) * | 2015-11-24 | 2016-04-13 | 陕西师范大学 | Application of two-dimensional lysozyme nanometer film as antibacterial material |
CN106479997A (en) * | 2016-11-28 | 2017-03-08 | 陕西师范大学 | Lysozyme nanocrystalline colloidal sol and the protein polycrystalline hydrogel prepared using which and preparation method |
CN110563979A (en) * | 2019-09-23 | 2019-12-13 | 陕西师范大学 | Protein nano-film based on exchange reaction of sulfydryl and disulfide bond and application thereof |
-
2022
- 2022-01-26 CN CN202210095697.XA patent/CN114470149B/en active Active
- 2022-01-26 CN CN202311404388.7A patent/CN117442702A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1616092A (en) * | 2004-10-19 | 2005-05-18 | 上海新药研究开发中心 | Compound lysoamidase spray agent and preparing method |
CN103520734A (en) * | 2013-09-29 | 2014-01-22 | 中国科学院过程工程研究所 | Albumin-based nano particle and preparation method and application thereof |
CN105475359A (en) * | 2015-11-24 | 2016-04-13 | 陕西师范大学 | Application of two-dimensional lysozyme nanometer film as antibacterial material |
CN109845761A (en) * | 2015-11-24 | 2019-06-07 | 陕西师范大学 | Application of the lysozyme two-dimensional nano-film as anti-biotic material |
CN106479997A (en) * | 2016-11-28 | 2017-03-08 | 陕西师范大学 | Lysozyme nanocrystalline colloidal sol and the protein polycrystalline hydrogel prepared using which and preparation method |
CN110563979A (en) * | 2019-09-23 | 2019-12-13 | 陕西师范大学 | Protein nano-film based on exchange reaction of sulfydryl and disulfide bond and application thereof |
Non-Patent Citations (3)
Title |
---|
JULING LI 等: "All-natural superhydrophobic coating for packaging and blood-repelling materials", 《CHEMICAL ENGINEERING JOURNAL》, vol. 410, pages 1 - 12 * |
YAN XU 等: "The Synthesis of a 2D Ultra-Large Protein Supramolecular Nanofilm by Chemoselective Thiol–Disulfide Exchange and its Emergent Functions", 《ANGEW. CHEM. INT. ED.》, vol. 59, pages 2850 - 2859 * |
吴正芳 等: "小分子识别诱导的溶菌酶准生理条件下相转变及应用", 《2013年全国高分子学术论文报告会论文摘要集——主题E:分子组装与超分子聚合物》, vol. 2, pages 212 - 218 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115531239A (en) * | 2022-05-19 | 2022-12-30 | 海默斯(重庆)医学生物技术有限公司 | Nano-particles, toothpaste and preparation method thereof |
CN115531239B (en) * | 2022-05-19 | 2023-12-12 | 海默斯(重庆)医学生物技术有限公司 | Nanoparticle, toothpaste and preparation method thereof |
CN115444031A (en) * | 2022-09-01 | 2022-12-09 | 陕西师范大学 | Protein-based fruit antibacterial fresh-keeping edible coating and preparation method and application thereof |
CN115843794A (en) * | 2022-12-13 | 2023-03-28 | 贵州大学 | Nano system of plant protein-based drug-encapsulated molecules, preparation method and application |
CN115843794B (en) * | 2022-12-13 | 2024-03-01 | 贵州大学 | Nanometer system of plant protein-based drug-encapsulated molecules and preparation method and application thereof |
WO2024179225A1 (en) * | 2023-02-28 | 2024-09-06 | 陕西师范大学 | Cleaning agent for material surface |
CN117777492A (en) * | 2023-11-14 | 2024-03-29 | 宁波大学 | Preparation method and application of normal-temperature antibacterial hydrogel based on fibrinogen and carrageenan |
CN117777492B (en) * | 2023-11-14 | 2024-09-27 | 宁波大学 | Preparation method and application of normal-temperature antibacterial hydrogel based on fibrinogen and carrageenan |
Also Published As
Publication number | Publication date |
---|---|
CN117442702A (en) | 2024-01-26 |
CN114470149B (en) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114470149B (en) | Antibacterial liquid with controllable-size protein-based nanoparticles | |
Ozdal et al. | Recent advances in nanoparticles as antibacterial agent | |
Goudie et al. | Characterization of an S-nitroso-N-acetylpenicillamine–based nitric oxide releasing polymer from a translational perspective | |
CN111773439B (en) | Biological friendly antibacterial coating capable of effectively fixing cationic antibacterial agent and resisting bacterial biofilm | |
Lequeux et al. | Addition of antimicrobial properties to hyaluronic acid by grafting of antimicrobial peptide | |
WO2019169873A1 (en) | Nano antibacterial gel for treating wound infection and promoting healing and preparation method therefor | |
CN110615829B (en) | Self-assembled antibacterial peptide hydrogel | |
CN101905034B (en) | Method for preparing biological polysaccharide self-assembly modificatory chitosan antibacterial biological material | |
CN110393725B (en) | Phenylboronic acid with gram selectivity and gold nanoparticle modified by derivative of phenylboronic acid, and preparation method and application of phenylboronic acid and gold nanoparticle | |
Chen et al. | Dual-functional antimicrobial coating based on the combination of zwitterionic and quaternary ammonium cation from rosin acid | |
Ul-Islam et al. | Chitosan-based nanostructured biomaterials: Synthesis, properties, and biomedical applications | |
Rani et al. | Evaluation of the antibacterial effect of silver nanoparticles on guided tissue regeneration membrane colonization—An in vitro study | |
CN112451738A (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
Bazaka et al. | Surface modification of biomaterials for biofilm control | |
Sun et al. | Recent progress of intelligent antibacterial nanoplatforms for treating bacterial infection | |
CN112480435B (en) | Injectable antibacterial hydrogel material and preparation method thereof | |
Sardelli et al. | Bioinspired in vitro intestinal mucus model for 3D-dynamic culture of bacteria | |
CN112089730A (en) | Antibacterial iron sulfide aqueous solution, preparation method and application thereof | |
CN103951732B (en) | A kind of antibacterial peptide | |
CN115304053A (en) | Carbon nanodot, injectable carbon nanodot-epsilon-polylysine hydrogel and preparation method and application thereof | |
CN111777670B (en) | PH-adjusted self-assembled antibacterial peptide and preparation method and application thereof | |
Fouad | Chitosan as an antimicrobial compound: modes of action and resistance mechanisms | |
CN111053917A (en) | Preparation method of intelligent efficient antibacterial agent based on protein | |
CN115246878B (en) | Antibacterial peptide and application thereof in cosmetics | |
Zvezdova | Applications of chitosan-sulfathiazole as antimicrobial agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |